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Abstract
Attention-Deficit/Hyperactivity Disorder is not a single pathophysiological entity and appears to have a complex
etiology. There are multiple genetic and environmental risk factors with small individual effect that act in concert
to create a spectrum of neurobiological liability. Structural imaging studies show that brains of children with Atten-
tion-Deficit/Hyperactivity Disorder are significantly smaller than unaffected controls. The prefrontal cortex, basal
ganglia and cerebellum are differentially affected and evidence indicating reduced connectivity in white matter
tracts in key brain areas is emerging. Genetic, pharmacological, imaging, and animal models highlight the impor-
tant role of dopamine dysregulation in the neurobiology of Attention-Deficit/Hyperactivity Disorder. To date, stimu-
lants are the most effective psychopharmacological treatments available for Attention-Deficit/Hyperactivity Disorder.
Currently only immediate release methylphenidate and atomoxetine are approved for the treatment of ADHD in
Italy. Drug treatment should always be part of a comprehensive plan that includes psychosocial, behavioural and
educational advice and interventions.
Introduction
Attention-Deficit/Hyperactivity Disorder (ADHD) is a
common, long-lasting, treatable childhood psychiatric
disorder, characterised by a pattern of developmentally
inappropriate inattention, motor restlessness, and impul-
sivity that affects approximately 3-7% of school-aged
children [1].
ADHD was first recognised 100 years ago as a child-
hood disorder found mainly in boys, and was initially
described as “hyperactivity” or “hyperkinetic disorder of
childhood”. This abnormal behaviour was found to be
the result of a biological condition rather than a result
of poor parenting [2]. In the 1960’sa n d7 0 ’sm u c ho f
the focus on what is now called ADHD was on hyperac-
tivity. The presence of excessive movements in children
was proposed to result from bilateral cortical activity
secondary to a lack of transcallosal fibre tract-mediated
interhemispheric inhibition [3]. Attention Deficit Disor-
der with or without Hyperactivity first featured in
DSM-III in 1980 [4], and the more recent DSM-IV-TR
provided updated ADHD criteria [5]. For a diagnosis of
ADHD, symptoms need to occur often, have persisted
for the past six months, and be maladaptive and incon-
gruent with the individual’s developmental level. Addi-
tionally, an ADHD diagnosis is only given if at least
some of the behavioural symptoms were present before
the age of 7 years, occur in more than one setting, and
cause significant impairment in social and school
functioning.
The renaming of the disorder, the subsequent focus on
attention, and the clarification of three subtypes led to a
range of neurocognitive and neurobiological hypotheses
regarding the etiology and pathophysiology of ADHD
w i t h i nam o r es p e c i f i cb r a i nlocalisation. Furthermore,
neurocognitive models of ADHD have become more
refined, and one particular executive process, inhibition,
is now considered to be a core deficit [6].
Current theories emphasise the central role of atten-
tional and executive dysfunctions in children [7,8], as
well as affective components involving emotional control
and motivational processes [9]. A growing body of evi-
dence supports a model in which multiple genetic and
environmental factors interact during early development
to create a neurobiological susceptibility to the disorder;
the expression of which is mediated by alterations within
different and diverse neural networks and deficits in the
neuropsychological functions that these subserve [10].
Individuals with ADHD present difficulties in several
domains of attentional and cognitive functions: problem
solving, planning, orienting, alerting, cognitive flexibility,
sustained attention, response inhibition, and working
memory [7,11]. Other domains involving affective com-
ponents, such as motivation and delay aversion, are also
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sensory motor coordination, including poor handwriting,
clumsiness, and marked delays in achieving motor mile-
stones [12], have also been reported and the prevalence
of motor impairment in the ADHD population has been
estimated to be approximately 50% [13]. Motor problems
might be partially related to abnormalities in structure
and/or function of the cerebellum and basal ganglia
found in ADHD [14].
Recently, neuroimaging has led to several important
advances in the understanding of the neurobiology
underlying the clinical picture of ADHD, and demon-
strates a clear brain basis to the disorder in regions
involved in attention, and executive and inhibitory con-
trol [15,16]. Furthermore, transcranial magnetic stimula-
tion (TMS) has provided evidence that intracortical
inhibition, as indexed by the immature ipsilateral motor
cortex, normalises with psychostimulant treatment [17].
There is an exciting confluence between emerging
studies in basic neurobiology and the genetic, neuroima-
ging, and neuropsychological analyses of ADHD. Knowl-
edge of neurobiology can offer child neurologists,
psychiatrists and other healthcare professionals a valu-
able framework for the interpretation of clinical findings
of children meeting the criteria for diagnosis of ADHD.
I nt h i sa r t i c l ew ep r o v i d eab rief overview of the salient
neurological basis of the disorder.
Etiology
ADHD is not a single pathophysiological entity and
appears to have a complex etiology. Multiple genetic
and environmental factors act together to create a spec-
trum of neurobiological liability.
The genetic basis for ADHD
Genetic factors are implicated in ADHD, but the
mechanism of action is not completely understood.
Twin, family and adoption studies of ADHD have sup-
ported a strong genetic contribution to the disorder,
with heritability ranging from 60-90% [18,19].
Genes regulating neurotransmitter systems have been
implicated in ADHD. Candidate gene studies of ADHD
have produced substantial evidence implicating several
genes in the etiology of the disorder, with meta-analyses
supportive of a role of the genes coding for DRD4,
DRD5, SLC6A3, SNAP-25, and HTR1B [20]. Genome
scan studies on potential alleles for ADHD have demon-
strated linkage on chromosomes 5p13, 6q12, 16p13,
17p11 and 11q22-25 [21,22]. However, genome-wide
association studies have failed to report any associations
that are significant after correction for multiple testing
[23]. Therefore, a plausible genetic hypothesis for
ADHD is a mixture of dominant and recessive major
genes that act with complex polygenic transmission
patterns [18]. An increased rate of large, rare, chromo-
somal deletions and duplications known as copy number
variants have been reported in individuals with ADHD
[24]. However, genetic testing in an individual child is
not currently practical in normal clinical practise.
Sometimes ADHD-like symptoms are exhibited by
patients with established neurogenetic disorders such as
Tuberous Sclerosis Complex, Neurofibromatosis I,
Turner Syndrome, Williams Syndrome, Velocardiofacial
syndrome, Prader-Willy syndrome, and Fragile × Syn-
drome. Although each syndrome may arise from differ-
ent genetic abnormalities with multiple molecular
functions, the effects of these abnormalities may give
rise to common effects downstream in the biological
pathways or neural circuits, resulting in the presentation
of ADHD symptoms [25].
The environmental basis of ADHD
Pre-, peri- and postnatal environmental factors play an
important role in the pathogenesis of ADHD. Prenatal
factors are associated with maternal lifestyle during
pregnancy. For example, prenatal alcohol exposure is
known to induce brain structural anomalies, especially
in the cerebellum [26]. Children exposed prenatally to
alcohol can become hyperactive, disruptive, impulsive,
and are at an increased risk of a range of psychiatric dis-
orders [27,28]. Maternal smoking produces a 2.7-fold
increased risk for ADHD [29], and a dose-response rela-
tionship between maternal smoking during pregnancy
and hyperactivity has been reported [30]. This may be
due to an effect on nicotinic receptors, which modulate
dopaminergic activity. Dopaminergic disruption is
believed to be involved in the pathophysiology of
ADHD [31,32].
Peri-natal factors have also been implicated, with a
two-fold increase in ADHD in very low-birthweight chil-
dren and an increased rate of pregnancy and birth com-
plications in mothers of children later diagnosed with
ADHD [33].
Among postnatal factors, a role for malnutrition and
dietary deficiency in ADHD has been proposed. An
imbalance of essential fatty acid (omega-3 and omega-6)
intake has been suggested to be potentially involved in
the development of ADHD [34], although further evi-
dence is required to establish a role. Iron deficiency has
been implicated in some cases [35]. Early deprivation of
social environment during the postnatal period may also
have significant effects.
Gene-environment interactions
More complex models of the etiology of ADHD incor-
porating gene-environment interplay need to be consid-
ered. Recent studies have focused on the joint effects of
gene variants (of DRD4 and DAT1) and prenatal
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demonstrating that smoking during pregnancy is asso-
ciated with the combined ADHD type in genetically sus-
ceptible children [36]. A significant interaction between
DAT1 genotype and prenatal smoke exposure was
found in males. Men homozygous for the DAT1
10-repeat allele had higher hyperactivity-impulsivity
than males from all other groups [37]. Despite the het-
erogeneity of the etiology and pathophysiology of
ADHD, abnormal DAT density seems to be common
among subjects with ADHD [38].
Neuroimaging
Growing evidence points to the involvement of the
frontostriatal network as a likely contributor to the
pathophysiology of ADHD. This network involves
the lateral prefrontal cortex, the dorsal anterior cingu-
late cortex, and the caudate nucleus and putamen. In
ADHD patients, reductions in volume have been
observed in total cerebral volume, the prefrontal cortex,
the basal ganglia (striatum), the dorsal anterior cingulate
cortex, the corpus callosum and the cerebellum [39].
A developmental trajectories study in ADHD patients
showed a delay in cortical maturation, and demon-
strated that different clinical outcomes may be asso-
ciated with different developmental trajectories in
adolescence and beyond [40]. In studies of cortical
development in children with ADHD, a marked delay in
brain maturation was seen; the grey matter peaks were
about 3 years later than in healthy controls [41]. The
delay was most prominent in prefrontal regions impor-
tant in the control of cognitive processes including
attention and motor planning [41,42]. Compensatory
networks including basal ganglia, insula and cerebellum
have been implicated for relative lower cognitive load
tasks in ADHD patients [43].
Neuroimaging studies have also reported reduced white
matter (WM) volumes [43], midsagittal corpus callosum
(CC) areas [44], and cortical thickness [43] in ADHD
patients compared with controls. One of the most repli-
cated alterations is a significantly smaller CC, but there
are conflicting reports regarding the affected callosal seg-
ments [45]. Recent magnetic resonance imaging (MRI)
structural investigations have shown that WM alterations
are present in children, adolescents and adults with
ADHD [46]. In 15 young males with ADHD, Silk et al.
(2008) found WM abnormalities in several distinct
regions underlying the inferior parietal, occipito-parietal,
inferior frontal, and inferior temporal cortex [47]. Tracto-
graphy methods showed that these regions form part of
WM pathways connecting prefrontal and parieto-occipi-
tal areas with the striatum and the cerebellum. The
authors also demonstrated anomalous WM development
in ADHD in distinct cortical regions that they had
previously shown to be dysfunctional or hypoactive in a
functional MRI study of subjects with ADHD [47].
Diffusion tensor imaging (DTI) is an MRI modality
that provides information about the direction and integ-
rity of neural fibre tracks in the brain in vivo.D T Is t u -
dies have revealed developmental changes in cortical
WM pathways in prefrontal regions and in pathways
surrounding the basal ganglia and cerebellum in patients
with ADHD, which presumably reflect decreasing myeli-
nation of axons. It is believed that these changes cause a
decrease in the speed of neuronal communication [48].
Moreover, the neural networks serving the corticostria-
tal and corticocerebellar circuits could represent puta-
tive biomarkers for ADHD. Indeed, in this disorder their
quantification using DTI could be relevant for both
diagnostic and therapeutic purposes [46].
As well as offering new data to map the brain systems
involved in ADHD, and to integrate these findings with
clinical symptoms, functional neuroimaging studies
allow us to understand the mechanisms of treatment
response [42,49]. Positron emission tomography (PET)
studies have shown that methylphenidate hydrochloride
(MPH) blocks dopamine active transporters (DAT) and
that extracellular dopamine (DA) increases in propor-
tion to the level of blockade and to the rate of DA
release. This process is associated with an enhanced per-
ception of the external stimulus as salient in subjects
with ADHD [50].
Clinical diagnosis and comorbidities
Clinical presentation of ADHD may vary according to
age and stage of development and there are cultural dif-
ferences in the level of activity and inattention that are
regarded as a problem [51]. Diagnosis requires that
there should be clear evidence of clinically significant
impairment in social, academic, or occupational func-
tioning [5]. The predominantly inattentive type is rela-
tively more common in females. Children with the
predominantly hyperactive-impulsive type are aggressive
and impulsive, and tend to be highly rejected by their
peers. The combined type causes more impairment in
global functioning, in comparison with the other two
types. Adolescents with ADHD often report low self-
esteem and poor peer relationships; and are at high risk
of smoking and substance abuse early in life [52,53].
Endophenotypes can be used as trait markers for dis-
ease susceptibility, to identify more genetically homoge-
neous subgroups, to highlight distinct pathophysiological
mechanisms or etiological pathways, or to define “spec-
trum” phenotypes suitable for quantitative trait analyses
[54]. Cognitive deficits and motor response inhibition are
the prime endophenotype candidates in ADHD [55].
The co-existence of several other types of psycho-
pathology along with ADHD, such as oppositional defiant
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tics, and mental retardation, is very common [56].
Treatment
Before starting treatment, it is important to identify the
target outcomes to guide the therapy decision. Drug
treatment should be based on a thorough assessment
and should always be part of a comprehensive treatment
plan that includes psychosocial, behavioural, and educa-
tional advice and interventions. Psychotherapy combined
with medication may play a role in treating behavioural
problems, organisational issues and psychiatric comor-
bidities [57]. In Italy, an ADHD diagnosis can only be
made at a regional referral centre approved by the Ita-
lian Ministry of Health. Treatment guidelines put for-
ward by the Ministry of Health and based on European
guidelines, specify that pharmacological treatment can
only be initiated after failure of cognitive behavioural
therapy over a period of 6 months or longer has been
demonstrated. Patients must first be enrolled in the
ADHD medication registry before treatment with MPH
or atomoxetine (ATX) can be prescribed.
Behavioural therapy and pharmacological treatment
have both been shown to benefit ADHD patients.
A longitudinal study of the efficacy of different treat-
ments (an intensively monitored medication program,
behavioural therapy, combination of medication and
behavioural therapy or treatment as usual by community
care) showed after 8-year follow-up that all four of the
original treatment groups had a similar outcome: all
showed improvement in comparison with pretreatment
baseline scores, but none demonstrated superiority [58].
The fronto-subcortical circuits (lateral prefrontal cor-
tex, dorsal anterior cingulate cortex, caudate, and puta-
men) associated with ADHD are rich in catecholamines,
which are involved in the mechanism of action of medi-
cations used to treat this disorder. Neuropharmacologi-
cal studies have provided evidence that ADHD involves
dysregulation of both noradrenaline (NE) and DA neu-
rotransmitter systems [59]. MPH treatment causes an
increase in DA signalling through multiple actions,
including blockade of the DA reuptake transporter,
amplification of DA response duration, disinhibition of
the dopamine D2 receptor and amplification of DA tone
[60]. MPH is also an inhibitor of NE re-uptake. ATX is
a selective inhibitor of synaptic re-uptake, and in vivo,i t
specifically increases extracellular levels of DA in the
prefrontal cortex but not in the striatum; probably by
modulating cortical synaptic DA uptake via the NE
transporter [61]. Dextroamphetamine increases the
synaptic activity of DA and NE by increasing the release
of the neurotransmitters into the synaptic cleft, decreas-
ing reuptake back into the presynaptic neuron, and inhi-
biting their catabolism [62]. Strong evidence exists
indicating that stimulant medications, such as MPH and
dextroamphetamine, and the non-stimulant ATX, are
effective in improving ADHD symptoms [63]. Guanfa-
cine is a selective alpha2A adrenergic receptor agonist,
which improves working memory by stimulating postsy-
naptic alpha2A adrenoceptors, strengthening the
functional connectivity of prefrontal cortex networks
[64]. Guanfacine has also been shown to be effective in
reducing ADHD symptoms [65,66]. Table 1 summarises
the most important characteristics of these pharmacolo-
gical treatments for ADHD. Only ATX and immediate
release MPH are currently approved for the treatment
of ADHD in Italy.
ADHD pharmacological therapies are generally well-
tolerated (Table 1). However, concerns surrounding the
cardiovascular safety of some of these drugs has
prompted a recent examination of the effects of ATX
and MPH on blood pressure (BP), heart rate (HR), and
ECG parameters. MPH appears to cause minor
increases in BP and HR, with no strong data to suggest
that itincreases the QT interval. Limited data suggest
that ATX may increase BP and HR in the short term;
in the long term it appears to only increase BP. The
effects of ATX on QT interval remain uncertain.
Because the current evidence is based on research that
has not been specifically designed to investigate the car-
diovascular effects of these drugs, it is difficult to draw
firm conclusions [67].
Both MPH and ATX significantly increase activation
in key cortical and subcortical regions subserving atten-
tion and executive functions. Therefore, alterations in
dopaminergic and noradrenergic function are apparently
necessary for the clinical efficacy of pharmacological
treatment of ADHD [68]. However MPH and ATX have
both common and distinct neural effects, consistent
with the observation that while many children respond
well to both treatments, some respond preferentially to
one or the other. Although pharmacotherapy for ADHD
appears to prepare and facilitate the brain for learning,
experiential programs need to elicit compensatory devel-
opment in the brain. The clinical amelioration of some
children after environmental experiential inputs and
early cognitive/behavioural treatment could indicate out-
come-associated plastic brain response [69]. One year of
treatment with MPH may be beneficial to show endur-
ing normalisation of neural correlates of attention. How-
ever, little is known about the long-term effects of
stimulants on the functional organisation of the devel-
oping brain [70]. Recent findings have shown that
chronic MPH use in drug-naive boys with ADHD
enhanced neuropsychological functioning on “recogni-
tion memory” component tasks with modest executive
demands [71]. Patients receiving pharmacological treat-
ment for ADHD should always be closely monitored for
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Conclusions
Convergent data from neuroimaging, neuropsychology,
genetics and neurochemical studies consistently point to
the involvement of the frontostriatal network as a likely
contributor to the pathophysiology of ADHD. This net-
work involves the lateral prefrontal cortex, the dorsal
anterior cingulate cortex and the caudate nucleus and
putamen [39]. Functional neuroimaging has provided
new ways to examine the pathophysiology of ADHD,
has shown widespread dysfunction in neural systems
involving the prefrontal, striatal, and parietal brain
regions, and has led to a brain model of deficits in mul-
tiple developmental pathways [72]. Molecular genetic
studies support dysregulation of neurotransmitter sys-
tems as the basis of genetic susceptibility to the disor-
der, and it is becoming clear that the genotype may
influence the response to medications [73]. Hopefully,
advances in understanding the underlying neurobiology
of ADHD will contribute to identifying more specific
and targeted pharmacotherapies, and will help child
neurologists to better manage their patients.
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Table 1 Clinical characteristics of ADHD pharmacotherapies
Pharmacotherapy Molecular mechanisms [59-66] Formulations Efficacy
(meta-analysis effect
size) [74,70]
Common adverse events
[75-79]
Stimulants
Methylphenidate Blocks DA reuptake transporter,
amplifies DA response duration,
disinhibits D2 receptor, inhibits NE
re-uptake
Immediate release 0.92 (0.80, 1.05) Decreased appetite, insomnia,
abdominal pain, headache dizziness,
reduced weight gain, affective
symptoms
Osmotic release 0.90 (0.76, 1.05) Decreased appetite, abdominal pain,
headache
Extended release 0.85 (0.65, 1.05) Decreased appetite, headache,
abdominal pain
Long-acting 0.96 (0.75, 1.16) Headache, insomnia, upper
abdominal pain, decreased appetite,
anorexia
Transdermal patch Not available Appetite, nausea, vomiting, insomnia
Dexmethylphenidate 0.76 (0.45, 1.08) Decreased appetite, headache,
abdominal pain, nausea
Dextroamphetamine Increases release of DA and NE into
synaptic cleft, decreases reuptake
into presynaptic neuron, inhibits
catabolism
Immediate release 1.24 (0.88, 1.60) Decreased appetite, insomnia
Extended release 1.13 (0.57, 1.69) Palpitations, tremor, insomnia,
decreased appetite, headache,
dizziness, dry mouth, weight loss,
abdominal symptoms
Prodrug 1.52 (1.34, 1.71) Decreased appetite, headache,
insomnia, abdominal pain, irritability
Mixed
amphetamine salts
Increases release of DA and NE into
synaptic cleft, decreases reuptake
into presynaptic neuron, inhibits
catabolism
Immediate release 1.34 (0.95, 1.72) Decreased appetite, agitation,
insomnia
Extended release 0.77 (0.59, 0.94) Decreased appetite, headache,
insomnia
Non-stimulants
Atomoxetine Selectively inhibits synaptic
DA re-uptake
Immediate release 0.63 (0.57, 0.69) Upper abdominal pain, decreased
appetite, vomiting, somnolence,
irritability, fatigue
Guanfacine Selective alpha2A adrenergic
receptor agonist
Immediate release Not available Sedation, insomnia, decreased
appetite, dry mouth, constipation
Extended release 0.8 (0.53, 1.07) Somnolence, fatigue, upper
abdominal pain, sedation
Curatolo et al. Italian Journal of Pediatrics 2010, 36:79
http://www.ijponline.net/content/36/1/79
Page 5 of 7Authors’ contributions
PC proposed and designed the study, and revised the final draft. EDA and
RM reviewed all the relevant articles on the literature, and prepared the first
draft under the supervision of Prof. Paolo Curatolo. All authors contributed
to the intellectual content and approved the final version.
Competing interests
Professor Paolo Curatolo has served as an Advisory Board Member for Eli
Lilly and Shire, and has received research grants from Eli Lilly and Shire. The
other authors have no conflicts of interest to declare.
Received: 3 November 2010 Accepted: 22 December 2010
Published: 22 December 2010
References
1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA: The worldwide
prevalence of ADHD: a systematic review and metaregression analysis.
Am J Psychiatry 2007, 164:942-948.
2. Still G: The Coulstonian lectures on some abnormal physical conditions
in children. Lecture 1. Lancet 1902, 1008-1012, 1077-1082, 1163-1168.
3. Denckla MB, Rudel RG: Anomalies of motor development in hyperactive
boys. Ann Neurol 1978, 3:231-233.
4. American Psychiatric Association: Diagnostic and Statistical Manual of Mental
Disorders. 3 (DSM-III) edition. Washington: American Psychiatric Association;
1980.
5. APA: Diagnostic and Statistical Manual of Mental Disorders. Fourth, Text
Revision edn. Washington 2000.
6. Barkley RA: Behavioral inhibition, sustained attention, and executive
functions: constructing a unifying theory of ADHD. Psychol Bull 1997,
121:65-94.
7. Sergeant JA, Geurts H, Huijbregts S, Scheres A, Oosterlaan J: The top and
the bottom of ADHD: a neuropsychological perspective. Neurosci
Biobehav Rev 2003, 27:583-592.
8. Castellanos FX, Sonuga-Barke EJ, Milham MP, Tannock R: Characterizing
cognition in ADHD: beyond executive dysfunction. Trends Cogn Sci 2006,
10:117-123.
9. Nigg JT, Casey BJ: An integrative theory of attention-deficit/hyperactivity
disorder based on the cognitive and affective neurosciences. Dev
Psychopathol 2005, 17:785-806.
10. Sonuga-Barke EJ, Halperin JM: Developmental phenotypes and causal
pathways in attention deficit/hyperactivity disorder: potential targets for
early intervention? J Child Psychol Psychiatry 51:368-389.
11. Pasini A, Paloscia C, Alessandrelli R, Porfirio MC, Curatolo P: Attention and
executive functions profile in drug naive ADHD subtypes. Brain Dev 2007,
29:400-408.
12. Piek JP, Pitcher TM, Hay DA: Motor coordination and kinaesthesis in boys
with attention deficit-hyperactivity disorder. Dev Med Child Neurol 1999,
41:159-165.
13. Racine MB, Majnemer A, Shevell M, Snider L: Handwriting performance in
children with attention deficit hyperactivity disorder (ADHD). J Child
Neurol 2008, 23:399-406.
14. Pasini A, D’Agati E: Pathophysiology of NSS in ADHD. World J Biol
Psychiatry 2009, 10:495-502.
15. Curatolo P: The neurology of attention deficit/hyperactivity disorder.
Brain Dev 2005, 27:541-543.
16. Suskauer SJ, Simmonds DJ, Fotedar S, Blankner JG, Pekar JJ, Denckla MB,
Mostofsky SH: Functional magnetic resonance imaging evidence for
abnormalities in response selection in attention deficit hyperactivity
disorder: differences in activation associated with response inhibition
but not habitual motor response. J Cogn Neurosci 2008, 20:478-493.
17. Hoeppner J, Wandschneider R, Neumeyer M, Gierow W, Haessler F,
Herpertz SC, Buchmann J: Impaired transcallosally mediated motor
inhibition in adults with attention-deficit/hyperactivity disorder is
modulated by methylphenidate. J Neural Transm 2008, 115:777-785.
18. Sharp SI, McQuillin A, Gurling HM: Genetics of attention-deficit
hyperactivity disorder (ADHD). Neuropharmacology 2009, 57:590-600.
19. Gizer IR, Ficks C, Waldman ID: Candidate gene studies of ADHD: a meta-
analytic review. Hum Genet 2009, 126:51-90.
20. Faraone SV, Mick E: Molecular genetics of attention deficit hyperactivity
disorder. Psychiatr Clin North Am 33:159-180.
21. Ogdie MN, Fisher SE, Yang M, Ishii J, Francks C, Loo SK, Cantor RM,
McCracken JT, McGough JJ, Smalley SL, Nelson SF: Attention deficit
hyperactivity disorder: fine mapping supports linkage to 5p13, 6q12,
16p13, and 17p11. Am J Hum Genet 2004, 75:661-668.
22. Coghill D, Banaschewski T: The genetics of attention-deficit/hyperactivity
disorder. Expert Rev Neurother 2009, 9:1547-1565.
23. Franke B, Vasquez AA, Johansson S, Hoogman M, Romanos J, Boreatti-
Hummer A, Heine M, Jacob CP, Lesch KP, Casas M, et al: Multicenter
Analysis of the SLC6A3/DAT1 VNTR Haplotype in Persistent ADHD
Suggests Differential Involvement of the Gene in Childhood and
Persistent ADHD. Neuropsychopharmacology 2009, 35(3):656-64.
24. Williams NM, Zaharieva I, Martin A, Langley K, Mantripragada K, Fossdal R,
Stefansson H, Stefansson K, Magnusson P, Gudmundsson OO, et al: Rare
chromosomal deletions and duplications in attention-deficit
hyperactivity disorder: a genome-wide analysis. Lancet 2010,
376(9750):1401-8.
25. Lo-Castro A, D’Agati E, Curatolo P: ADHD and genetic syndromes. Brain
Dev 2010.
26. Coffin JM, Baroody S, Schneider K, O’Neill J: Impaired cerebellar learning in
children with prenatal alcohol exposure: a comparative study of
eyeblink conditioning in children with ADHD and dyslexia. Cortex 2005,
41:389-398.
27. D’Onofrio BM, Van Hulle CA, Waldman ID, Rodgers JL, Rathouz PJ, Lahey BB:
Causal inferences regarding prenatal alcohol exposure and childhood
externalizing problems. Arch Gen Psychiatry 2007, 64:1296-1304.
28. Sen B, Swaminathan S: Maternal prenatal substance use and behavior
problems among children in the U.S. J Ment Health Policy Econ 2007,
10:189-206.
29. Milberger S, Biederman J, Faraone SV, Chen L, Jones J: Is maternal smoking
during pregnancy a risk factor for attention deficit hyperactivity disorder
in children? Am J Psychiatry 1996, 153:1138-1142.
30. Kotimaa AJ, Moilanen I, Taanila A, Ebeling H, Smalley SL, McGough JJ,
Hartikainen AL, Jarvelin MR: Maternal smoking and hyperactivity in 8-
year-old children. J Am Acad Child Adolesc Psychiatry 2003, 42:826-833.
31. Potter AS, Newhouse PA, Bucci DJ: Central nicotinic cholinergic systems: a
role in the cognitive dysfunction in attention-deficit/hyperactivity
disorder? Behav Brain Res 2006, 175:201-211.
32. Weiss S, Tzavara ET, Davis RJ, Nomikos GG, Michael McIntosh J, Giros B,
Martres MP: Functional alterations of nicotinic neurotransmission in
dopamine transporter knock-out mice. Neuropharmacology 2007,
52:1496-1508.
33. Taylor E, Rogers JW: Practitioner review: early adversity and
developmental disorders. J Child Psychol Psychiatry 2005, 46:451-467.
34. Raz R, Gabis L: Essential fatty acids and attention-deficit-hyperactivity
disorder: a systematic review. Dev Med Child Neurol 2009, 51:580-592.
35. Juneja M, Jain R, Singh V, Mallika V: Iron Deficiency in Indian Children
with Attention Deficit Hyperactivity Disorder. Indian Pediatr 2010,
47(11):955-8.
36. Neuman RJ, Lobos E, Reich W, Henderson CA, Sun LW, Todd RD: Prenatal
smoking exposure and dopaminergic genotypes interact to cause a
severe ADHD subtype. Biol Psychiatry 2007, 61:1320-1328.
37. Becker K, El-Faddagh M, Schmidt MH, Esser G, Laucht M: Interaction of
dopamine transporter genotype with prenatal smoke exposure on
ADHD symptoms. J Pediatr 2008, 152:263-269.
38. Spencer TJ, Biederman J, Madras BK, Faraone SV, Dougherty DD, Bonab AA,
Fischman AJ: In vivo neuroreceptor imaging in attention-deficit/
hyperactivity disorder: a focus on the dopamine transporter. Biol
Psychiatry 2005, 57:1293-1300.
39. Emond V, Joyal C, Poissant H: [Structural and functional neuroanatomy of
attention-deficit hyperactivity disorder (ADHD)]. Encephale 2009,
35:107-114.
40. Shaw P, Rabin C: New insights into attention-deficit/hyperactivity
disorder using structural neuroimaging. Curr Psychiatry Rep 2009,
11:393-398.
41. Shaw P, Lerch J, Greenstein D, Sharp W, Clasen L, Evans A, Giedd J,
Castellanos FX, Rapoport J: Longitudinal mapping of cortical thickness
and clinical outcome in children and adolescents with attention-deficit/
hyperactivity disorder. Arch Gen Psychiatry 2006, 63:540-549.
42. Shaw P, Eckstrand K, Sharp W, Blumenthal J, Lerch JP, Greenstein D,
Clasen L, Evans A, Giedd J, Rapoport JL: Attention-deficit/hyperactivity
Curatolo et al. Italian Journal of Pediatrics 2010, 36:79
http://www.ijponline.net/content/36/1/79
Page 6 of 7disorder is characterized by a delay in cortical maturation. Proc Natl Acad
Sci USA 2007, 104:19649-19654.
43. Castellanos FX, Lee PP, Sharp W, Jeffries NO, Greenstein DK, Clasen LS,
Blumenthal JD, James RS, Ebens CL, Walter JM, et al: Developmental
trajectories of brain volume abnormalities in children and adolescents
with attention-deficit/hyperactivity disorder. JAMA 2002, 288:1740-1748.
44. Krain AL, Castellanos FX: Brain development and ADHD. Clin Psychol Rev
2006, 26:433-444.
45. Luders E, Narr KL, Hamilton LS, Phillips OR, Thompson PM, Valle JS,
Del’Homme M, Strickland T, McCracken JT, Toga AW, Levitt JG: Decreased
callosal thickness in attention-deficit/hyperactivity disorder. Biol Psychiatry
2009, 65:84-88.
46. Makris N, Buka SL, Biederman J, Papadimitriou GM, Hodge SM, Valera EM,
Brown AB, Bush G, Monuteaux MC, Caviness VS, et al: Attention and
executive systems abnormalities in adults with childhood ADHD: A DT-
MRI study of connections. Cereb Cortex 2008, 18:1210-1220.
47. Silk TJ, Vance A, Rinehart N, Bradshaw JL, Cunnington R: White-matter
abnormalities in attention deficit hyperactivity disorder: A diffusion
tensor imaging study. Hum Brain Mapp 2009, 30(9):2757-65a.
48. D’Agati E, Casarelli L, Pitzianti MB, Pasini A: Overflow movements and
white matter abnormalities in ADHD. Prog Neuropsychopharmacol Biol
Psychiatry 34:441-445.
49. Bush G, Spencer TJ, Holmes J, Shin LM, Valera EM, Seidman LJ, Makris N,
Surman C, Aleardi M, Mick E, Biederman J: Functional magnetic resonance
imaging of methylphenidate and placebo in attention-deficit/
hyperactivity disorder during the multi-source interference task. Arch
Gen Psychiatry 2008, 65:102-114.
50. Volkow ND, Wang GJ, Fowler JS, Ding YS: Imaging the effects of
methylphenidate on brain dopamine: new model on its therapeutic
actions for attention-deficit/hyperactivity disorder. Biol Psychiatry 2005,
57:1410-1415.
51. Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J,
Coghill D, Danckaerts M, Rothenberger A, Sonuga-Barke E, et al: European
clinical guidelines for hyperkinetic disorder - first upgrade. Eur Child
Adolesc Psychiatry 2004, 13(Suppl 1):I7-30.
52. Elkins IJ, McGue M, Iacono WG: Prospective effects of attention-deficit/
hyperactivity disorder, conduct disorder, and sex on adolescent
substance use and abuse. Arch Gen Psychiatry 2007, 64:1145-1152.
53. Loe IM, Feldman HM: Academic and educational outcomes of children
with ADHD. J Pediatr Psychol 2007, 32:643-654.
54. Crosbie J, Perusse D, Barr CL, Schachar RJ: Validating psychiatric
endophenotypes: inhibitory control and attention deficit hyperactivity
disorder. Neurosci Biobehav Rev 2008, 32:40-55.
55. Goos LM, Crosbie J, Payne S, Schachar R: Validation and extension of the
endophenotype model in ADHD patterns of inheritance in a family
study of inhibitory control. Am J Psychiatry 2009, 166:711-717.
56. Biederman J, Faraone SV: Attention-deficit hyperactivity disorder. Lancet
2005, 366:237-248.
57. Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB,
Clevenger W, Davies M, Elliott GR, Greenhill LL, et al: Clinical relevance of
the primary findings of the MTA: success rates based on severity of
ADHD and ODD symptoms at the end of treatment. J Am Acad Child
Adolesc Psychiatry 2001, 40:168-179.
58. Molina BS, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, Jensen PS,
Epstein JN, Hoza B, Hechtman L, Abikoff HB, et al: The MTA at 8 years:
prospective follow-up of children treated for combined-type ADHD in a
multisite study. J Am Acad Child Adolesc Psychiatry 2009, 48:484-500.
59. Pliszka SR: The neuropsychopharmacology of attention-deficit/
hyperactivity disorder. Biol Psychiatry 2005, 57:1385-1390.
60. Wilens TE: Effects of methylphenidate on the catecholaminergic system
in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2008,
28:S46-53.
61. Swanson CJ, Perry KW, Koch-Krueger S, Katner J, Svensson KA, Bymaster FP:
Effect of the attention deficit/hyperactivity disorder drug atomoxetine
on extracellular concentrations of norepinephrine and dopamine in
several brain regions of the rat. Neuropharmacology 2006, 50:755-760.
62. Solanto MV: Neuropsychopharmacological mechanisms of stimulant drug
action in attention-deficit hyperactivity disorder: a review and
integration. Behav Brain Res 1998, 94:127-152.
63. Biederman J, Spencer TJ: Psychopharmacological interventions. Child
Adolesc Psychiatr Clin N Am 2008, 17:439-458.
64. Wang M, Ramos BP, Paspalas CD, Shu Y, Simen A, Duque A,
Vijayraghavan S, Brennan A, Dudley A, Nou E, et al: Alpha2A-adrenoceptors
strengthen working memory networks by inhibiting cAMP-HCN channel
signaling in prefrontal cortex. Cell 2007, 129:397-410.
65. Sallee FR, Lyne A, Wigal T, McGough JJ: Long-term safety and efficacy of
guanfacine extended release in children and adolescents with attention-
deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009,
19:215-226.
66. Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Biederman J:
Guanfacine extended release in children and adolescents with attention-
deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child
Adolesc Psychiatry 2009, 48:155-165.
67. Stiefel G, Besag FM: Cardiovascular effects of methylphenidate,
amphetamines and atomoxetine in the treatment of attention-deficit
hyperactivity disorder. Drug Saf 2010, 33:821-842.
68. Stahl SM: Mechanism of action of stimulants in attention-deficit/
hyperactivity disorder. J Clin Psychiatry 71:12-13.
69. Rapoport JL, Gogtay N: Brain neuroplasticity in healthy, hyperactive and
psychotic children: insights from neuroimaging.
Neuropsychopharmacology 2008, 33:181-197.
70. Konrad K, Neufang S, Fink GR, Herpertz-Dahlmann B: Long-term effects of
methylphenidate on neural networks associated with executive
attention in children with ADHD: results from a longitudinal functional
MRI study. J Am Acad Child Adolesc Psychiatry 2007, 46:1633-1641.
71. Coghill DR, Rhodes SM, Matthews K: The neuropsychological effects of
chronic methylphenidate on drug-naive boys with attention-deficit/
hyperactivity disorder. Biol Psychiatry 2007, 62:954-962.
72. Sonuga-Barke EJ: Causal models of attention-deficit/hyperactivity
disorder: from common simple deficits to multiple developmental
pathways. Biol Psychiatry 2005, 57:1231-1238.
73. Gilbert DL, Wang Z, Sallee FR, Ridel KR, Merhar S, Zhang J, Lipps TD,
White C, Badreldin N, Wassermann EM: Dopamine transporter genotype
influences the physiological response to medication in ADHD. Brain
2006, 129:2038-2046.
74. Faraone SV: Using Meta-analysis to Compare the Efficacy of Medications
for Attention-Deficit/Hyperactivity Disorder in Youths. PT2009,
34:678-694.
75. Kratochvil CJ, Milton DR, Vaughan BS, Greenhill LL: Acute atomoxetine
treatment of younger and older children with ADHD: a meta-analysis of
tolerability and efficacy. Child Adolesc Psychiatry Ment Health 2008, 2:25.
76. Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, Scherer N:
A randomized, double-blind, placebo-controlled study of guanfacine
extended release in children and adolescents with attention-deficit/
hyperactivity disorder. Pediatrics 2008, 121:e73-84.
77. Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E,
Arnsten AF, Cohen DJ, Leckman JF: A placebo-controlled study of
guanfacine in the treatment of children with tic disorders and attention
deficit hyperactivity disorder. Am J Psychiatry 2001, 158:1067-1074.
78. Faraone SV, Pucci M, Coghill D: Pharmacotherapy for Attention-deficit
Hyperactivity disorder. Eur Psych Review 2009, 2:42-52.
79. Biederman J, Quinn D, Weiss M, Markabi S, Weidenman M, Edson K,
Karlsson G, Pohlmann H, Wigal S: Efficacy and safety of Ritalin LA, a new,
once daily, extended-release dosage form of methylphenidate, in
children with attention deficit hyperactivity disorder. Paediatr Drugs 2003,
5:833-841.
doi:10.1186/1824-7288-36-79
Cite this article as: Curatolo et al.: The neurobiological basis of ADHD.
Italian Journal of Pediatrics 2010 36:79.
Curatolo et al. Italian Journal of Pediatrics 2010, 36:79
http://www.ijponline.net/content/36/1/79
Page 7 of 7